We Participated in the CPH placement - and so did Billionaire John Hancock
Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio.
CPH is a global medical cannabis company that is about to settle the acquisition of a promising psychedelics start up.
Today, we increased our position in CPH via the company’s placement (as you may have noticed we have been pretty active in participating in placements the last few weeks).
CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.
This investment is in addition to what has become a pretty big holding from our initial position that started as a medium term trade in late 2020.
We have updated our investment strategy for CPH and are now planning to hold for the medium to long term.
We also welcome Billionaire Rich Lister John Hancock to the CPH register - after he also invested in our 2020 Small Cap Pick of the Year Vulcan Energy Resources - wouldn't it be great if CPH got a similar result.
John, feel free to reach out if you ever want to chat about our growing number of co-investments. 😬
Here’s why we like CPH right now
CPH’s USA listing on the OTC is expected in the coming weeks
Over the last few weeks, another company in our Portfolio, 88 Energy, has had a very strong run off the back of new US investors getting into the story though Reddit Groups. We were blown away by the momentum that has been generated.
So we have seen what retail investors in the USA can do to dual listed companies like 88 Energy...
... And we know that CPH isn't shy about promoting itself.
We get an email from HotCopper about CPH on almost every announcement the company makes, which raises awareness amongst new investors each time - we are always fans of companies that know how to get their story out there.
So based on what we’ve seen, we expect CPH will aggressively promote its story in the USA once it is listed there in the coming weeks: the USA is a way bigger investor market than Australia.
We hope that CPH will find it easy to get attention over there, especially given today’s announcement by New York state that will see it legalise recreational cannabis.
CPH recently entered Psychedelics
We wrote about CPH’s entry into psychedelics a few weeks ago. The market did not seem to care about this news - but we really liked it.
Psychedelics are a class of substances widely tipped to lead a massive transformation in mental health care over the coming decade.
Over a billion people worldwide have depression, anxiety, or post-traumatic stress syndrome or are dealing with substance abuse.
Studies have shown that psychedelics may be able to treat disorders such as depression, anxiety, substance addiction, and obsessive compulsive disorders.
Serious early stage investors (think private equity and venture capital) are making massive bets on the rapidly emerging psychedelics industry:
- CNBC: Peter Thiel backs Berlin start-up making psychedelics in $125 million round
- Business Insider: Kevin O'Leary of 'Shark Tank': Why I'm betting big on psychedelics, and how investors should be thinking about this opportunity
- Bloomberg: ‘Magic Mushroom’ Company Goes Mainstream, Jumps 71% Post-IPO
- Forbes: NYU Establishes Center For Psychedelic Medicine With $10 Million From MindMed, Philanthropists
- Fortune: Business gets ready to trip: How psychedelic drugs may revolutionize mental health care
Psychedelics Peer Comparisons
Mindmed is capped at over $1BN, and is also listed on the OTC.
Compass Pathways is capped at $1.36BN and listed on NASDAQ..
CPH has a $224M market cap and a strong cannabis business as well. We would like to think CPH can start catching up to its North American peers once listed on the OTC.
So what’s next?
CPH has been a bumpy ride for us all over the last few years.
After riding the share price up, (then all the way down) following a failed $122M acquisition in June 2019, we decided to re-enter CPH as a short term trade in early October 2020 at 3c.
As planned, we sold a portion of our position and locked in some profits (unfortunately for us we comprehensively missed the high point...).
In January, we changed our plan and decided to hold onto a significant position in CPH for at least three to six months, after we were encouraged by the progress made by the company on its turnaround plan and the CPH share price performance.
Looking forward, the CPH share price seems to have consolidated around 20c and a $224M market cap and the company has begun 2021 with record sales and purchase orders.
We are close to adding CPH to our long term portfolio after investing in the placement this week and with the upcoming USA listing, its entry into the Psychedelic space, and an $18M capital raise complete.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.